136 related articles for article (PubMed ID: 10081867)
1. Downward trend in prostate cancer mortality in Quebec and Canada.
Meyer F; Moore L; Bairati I; Fradet Y
J Urol; 1999 Apr; 161(4):1189-91. PubMed ID: 10081867
[TBL] [Abstract][Full Text] [Related]
2. Quebec prostate cancer mortality dropped in 1996.
Meyer F; Moore L; Bairati I; Fradet Y
Cancer Prev Control; 1998 Aug; 2(4):163-6. PubMed ID: 10093628
[TBL] [Abstract][Full Text] [Related]
3. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
[TBL] [Abstract][Full Text] [Related]
4. Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates.
Di Matteo L; Di Matteo R
Eur J Health Econ; 2005 Dec; 6(4):298-308. PubMed ID: 16180027
[TBL] [Abstract][Full Text] [Related]
5. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
Merrill RM; Stephenson RA
J Urol; 2000 Feb; 163(2):503-10. PubMed ID: 10647666
[TBL] [Abstract][Full Text] [Related]
6. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
8. Impact of screening on prostate cancer rates and trends.
Mettlin C
Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
[TBL] [Abstract][Full Text] [Related]
9. PSA screening and prostate cancer mortality.
Perron L; Moore L; Bairati I; Bernard PM; Meyer F
CMAJ; 2002 Mar; 166(5):586-91. PubMed ID: 11898936
[TBL] [Abstract][Full Text] [Related]
10. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial.
Labrie F; Candas B; Cusan L; Gomez JL; Bélanger A; Brousseau G; Chevrette E; Lévesque J
Prostate; 2004 May; 59(3):311-8. PubMed ID: 15042607
[TBL] [Abstract][Full Text] [Related]
11. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality.
Bartsch G; Horninger W; Klocker H; Pelzer A; Bektic J; Oberaigner W; Schennach H; Schäfer G; Frauscher F; Boniol M; Severi G; Robertson C; Boyle P;
BJU Int; 2008 Apr; 101(7):809-16. PubMed ID: 18321314
[TBL] [Abstract][Full Text] [Related]
12. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
Feuer EJ; Mariotto A; Merrill R
Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer and the Will Rogers phenomenon.
Albertsen PC; Hanley JA; Barrows GH; Penson DF; Kowalczyk PD; Sanders MM; Fine J
J Natl Cancer Inst; 2005 Sep; 97(17):1248-53. PubMed ID: 16145045
[TBL] [Abstract][Full Text] [Related]
14. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
15. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Brenner H; Arndt V
J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Konety BR; Bird VY; Deorah S; Dahmoush L
J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
[TBL] [Abstract][Full Text] [Related]
18. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.
Oberaigner W; Horninger W; Klocker H; Schönitzer D; Stühlinger W; Bartsch G
Am J Epidemiol; 2006 Aug; 164(4):376-84. PubMed ID: 16829552
[TBL] [Abstract][Full Text] [Related]
19. International trends in prostate-cancer mortality: the decrease is continuing and spreading.
Baade PD; Coory MD; Aitken JF
Cancer Causes Control; 2004 Apr; 15(3):237-41. PubMed ID: 15090718
[TBL] [Abstract][Full Text] [Related]
20. Recent changes in the spatial pattern of prostate cancer in the U.S.
Rogerson PA; Sinha G; Han D
Am J Prev Med; 2006 Feb; 30(2 Suppl):S50-9. PubMed ID: 16458790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
